Canadians face a longer-than-expected wait for cheaper versions of Novo Nordisk A/S’s diabetes drug Ozempic after two of the biggest generics makers were hit with additional requests from the health regulator.
Sandoz Group AG received a notice of deficiency from Health Canada — meaning a drug doesn’t yet meet regulatory requirements — for the Swiss drugmaker’s copycat version of semaglutide, Ozempic’s main ingredient, according to a person familiar with the matter who spoke on condition of anonymity.